In accordance with one or more embodiments, the present invention provides a compound of formulas I, II, and III, for use in methods of inhibition of PBX1-DNA interaction in a mammalian cell or population of cells, and for use in the treatment of medical conditions including but not limited to cancers, developmental disorders, inflammatory disorders, autoimmune diseases, or neuro-degenerative disorders.

[PROBLEM] To provide a novel method for synthesising a polyphenol.

[SOLUTION] A polyphenol production method including the reaction of catechin in the presence of a catalyst and an oxidising agent, said catalyst comprising a metal oxide and/or a composite that comprises: a substrate which has an inorganic material on the surface thereof; and metal nanoparticles of a particle diameter of 0.5-100 nm attached to the surface of the inorganic material.

[PROBLEM] To provide a novel method for synthesising a polyphenol.

[SOLUTION] A polyphenol production method including the reaction of catechin in the presence of a catalyst and an oxidising agent, said catalyst comprising a metal oxide and/or a composite that comprises: a substrate which has an inorganic material on the surface thereof; and metal nanoparticles of a particle diameter of 0.5-100 nm attached to the surface of the inorganic material.

The present application describes process for preparing an ortho-allylated hydroxy aryl compounds such as compounds of Formula (1) by reacting an allylic alcohol with a hydroxy aryl compound in the presence of aluminum compound selected from alumina and aluminum alkoxides and in a non-protic solvent wherein at least one carbon atom ortho to the hydroxy group in the hydroxy aryl compound is unsubstituted. The present application also includes compounds of Formula (1).

##STR00001##

The present invention provides a myricetin derivative, a preparation method thereof, a pharmaceutical composition containing the same, an application thereof for treating colitis, preventing and treating colitis-associated tumorigenesis and treating colorectal cancer, and an application thereof in preparing a composition for modulating activities of endoplasmic reticulum stress signaling molecules. The myricetin derivative disclosed herein has excellent water solubility, and has biological activities including inhibition of colitis, prevention and treatment of colitis-associated tumorigenesis, and treatment of colorectal cancer. The preparation method disclosed herein uses myricetrin as starting material which is economical and easily available. With the merits of low cost, high yield, high product purity and suitability for large-scale industrial production, the preparation method disclosed herein represents significant market value and economic prospects.

The present invention provides a myricetin derivative, a preparation method thereof, a pharmaceutical composition containing the same, an application thereof for treating colitis, preventing and treating colitis-associated tumorigenesis and treating colorectal cancer, and an application thereof in preparing a composition for modulating activities of endoplasmic reticulum stress signaling molecules. The myricetin derivative disclosed herein has excellent water solubility, and has biological activities including inhibition of colitis, prevention and treatment of colitis-associated tumorigenesis, and treatment of colorectal cancer. The preparation method disclosed herein uses myricetrin as starting material which is economical and easily available. With the merits of low cost, high yield, high product purity and suitability for large-scale industrial production, the preparation method disclosed herein represents significant market value and economic prospects.

The disclosure aims to provide a chemical synthesis method of a prodelphinidin B9 gallate, in which the prodelphinidin B9 gallate is synthesized by using a proanthocyanidin from Chinese bayberry leaves as a raw material, and using epigallocatechin gallate (EGCG) as a nucleophilic reagent to attack C4 sites of subunits EGCG and epigallocatechin (EGC) of the proanthocyanidin from Chinese bayberry leaves in the presence of hydrochloric acid as a catalyst. Compared with prodelphinidin B9 gallates extracted and separated from materials such as tea leaves, and Chinese bayberry leaves, the prodelphinidin B9 gallate prepared by the method provided in the present disclosure has higher purity and yield, and can be directly used as a nutrient enhancer and a natural antioxidant in the field of food.

The disclosure aims to provide a chemical synthesis method of a prodelphinidin B9 gallate, in which the prodelphinidin B9 gallate is synthesized by using a proanthocyanidin from Chinese bayberry leaves as a raw material, and using epigallocatechin gallate (EGCG) as a nucleophilic reagent to attack C4 sites of subunits EGCG and epigallocatechin (EGC) of the proanthocyanidin from Chinese bayberry leaves in the presence of hydrochloric acid as a catalyst. Compared with prodelphinidin B9 gallates extracted and separated from materials such as tea leaves, and Chinese bayberry leaves, the prodelphinidin B9 gallate prepared by the method provided in the present disclosure has higher purity and yield, and can be directly used as a nutrient enhancer and a natural antioxidant in the field of food.

In accordance with one or more embodiments, the present invention provides a compound of formulas I, II, and III, for use in methods of inhibition of PBX1-DNA interaction in a mammalian cell or population of cells, and for use in the treatment of medical conditions including but not limited to cancers, developmental disorders, inflammatory disorders, autoimmune diseases, or neuro-degenerative disorders.

The invention relates to new PI3K/AKT/m TOR inhibitors and their use for the prevention and/or the treatment of a disease selected from the group consisting of: inflammatory diseases, autoimmune diseases, neurodegenerative diseases, cancers, transplant rejection, diseases characterized by a premature aging and tuberous sclerosis.